Invion will work with 3M Drug Delivery Systems to develop inhaled formulations of nadolol and zafirlukast to be delivered using 3M’s MDI technology. If inhaled delivery of INV102 (nadolol) and INV104 (zafirlukast) for the treatment of asthma, COPD, and CF proves feasible, the two companies plan to develop the products through to commercialization.
Invion is already developing oral nadolol, a beta blocker, for mild asthma and for smoking cessation in COPD patients. Both indications are in Phase 2 development.
The company acquired a worldwide license to develop inhaled formulations of zafirlukast, a leukotriene receptor antagonist, from Accolade Pharma in 2013.
Invion Managing Director and CEO Greg Collier commented, “Invion’s products are especially suitable for combination with existing respiratory drugs because of their unique anti-inflammatory profiles. Presuming we can demonstrate safety and efficacy with this delivery system, it will make both INV102 and INV104 even more attractive propositions. . . . 3M is a world leader in innovation with a comprehensive drug delivery portfolio. This collaboration with 3M is important to the potential of Invion’s drug assets, and a solid step forward for our programs.”
Read the Invion press release.
